Skip to main content

Main menu

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Reprint Information
    • Feedback
    • Email Alerts
  • ASN Kidney News
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology

User menu

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Reprint Information
    • Feedback
    • Email Alerts
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow Kidney360 on Twitter
  • Community Forum
  • Kidney360 RSS
Moderator Commentary

Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY

Ali K. Abu-Alfa
Kidney360 January 2021, 2 (1) 16-19; DOI: https://doi.org/10.34067/KID.0006002020
Ali K. Abu-Alfa
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ali K. Abu-Alfa
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • chronic kidney disease
  • gadolinium
  • magnetic resonance imaging
  • nephrogenic systemic fibrosis

In 2006, the first reported association between an antecedent exposure to gadolinium‐based contrast media (GBCM) and the development of nephrogenic systemic fibrosis (NSF) ignited a debate on the safety of these agents in patients with kidney disease, with ensuing severe and appropriate-use restrictions put in place. In this issue of Kidney360, this debate is revived 15 years later, but with the tide reversing as their use is being reconsidered in these same patients. This debilitating, and often fatal, disease has fortunately receded into memory for many nephrologists. Its practical disappearance can be credited to both the implementation of protocols limiting GBCM use in patients with impaired kidney function or those on maintenance dialysis and the contraindication in those with CKD stages 4–5D or AKI (by the Food and Drug Administration [FDA] and the European Medicines Agency [EMA]) of the three most offending group I or high‐risk GBCM, as per the American College of Radiology classification (Table 1) (1). Restrictions on the use of the other available GBCM in patients with kidney disease remain in place today at many centers around the world. In fact, the FDA black-box warning for group II, or low‐risk, agents still carry a cautionary note on their use in patients with kidney disease. Recent data have emerged highlighting the safety of these agents in both patients with CKD stages 4–5 and those with ESKD, thus prompting a re‐evaluation of practice and policies. The recent calls to revisit the restrictions in place take into consideration their unintended consequences, such as the acquisition of suboptimal diagnostic studies, a concern no longer overshadowed by the risk for NSF.

View this table:
  • View inline
  • View popup
Table 1.

Classification of gadolinium‐based media according to their risk for nephrogenic systemic fibrosis by three organizations

Although the majority of initial NSF reports were in patients with ESKD, 8% of patients reported at the peak of cases of NSF had CKD stages 4–5 and had received high-risk agents, especially gadodiamide (2). The interaction between GFR and GBCM type is clearly strongest for high‐risk GBCM, but may not exist for low‐risk ones. Of note, the intravenous use of high‐risk GBCM in any patient was suspended by EMA in 2017, mostly over concern of gadolinium brain deposition, and these agents are no longer marketed in the United States.

As such, it is important for nephrologists to be aware of GBCM types because their chemical structures appear to underlie their classification according to NSF risk by the ACR, EMA, and European Society of Urogenital Radiology (ESUR). As shown in Table 1, the main difference between ACR and EMA/ESUR is the inclusion of gadobenate dimeglumine among group II agents by ACR, but this agent is included in the intermediate- or medium‐risk group by EMA/ESUR, along with limiting its use to hepatobiliary imaging. Nonetheless, its associated risk was quite low in two recent studies that included 154 patients with CKD stages 4–5 (3,4). These findings are seconded in the recent subanalysis of a large meta-analysis dataset with no patients with NSF identified among 2687 patients with CKD stages 4–5 who were exposed to group II GBCM (5,6).

Because I have already declared a position in favor of lifting restrictions on the use of group II GBCM in those with CKD (7), it is important to start this discussion by first heeding the expressed concerns raised by Pun and Crowley (8) in their con paper. The authors raise a number of important points, relying on data from a project of the US Veteran Affairs Evidence Synthesis Program (9). In 19 cohort studies and one nonrandomized trial with exclusive use of group II GBCM (except for one group III GBCM), no cases of NSF were identified in 83,291 patients. As noted, the CKD stages 3–5D subgroup represented <5% of the total, raising concern for representation and inclusiveness, especially that restrictive policies have likely excluded patients with CKD from getting GBCM. Nonetheless, there were no patients who developed NSF, including in patients with ESKD who were historically considered the most at risk with group I GBCM. In the recent, aforementioned subanalysis, there were 2666 patients with CKD stages 4–5 who were receiving either gadobenate or gadoterate, among whom 27% had CKD stage 5 and 32% received gadoterate. No patients with NSF were reported, with a recalculated risk of one in 694 exposed for this subgroup. Despite a smaller than desired number of collated patients with CKD stages 4–5 in cohort studies, the absence of NSF is reassuring. On the basis of NSF cases occuring in 40 patients with CKD stages 4–5, a modeled risk was calculated at one in 908 exposed to high‐risk GBCM, and there was a predicted nil risk for low‐risk GBCM (2). This can be seen as reassuring because risk was infinitesimally small in CKD stages 4–5, even with high‐risk agents, and practically nil with low‐risk II GBCM.

Inherent limitations to all of the included studies are raised by the authors, such as the lack of standardized assessment for NSF, despite published diagnostic criteria (10), and repeated administrations. Of note, an interesting point is made about patients with risk factors for CKD not being included, although NSF risk has been confined to presence of CKD per se. Informed consent is not recommended prior to GBCA group II injection, but deference is made to local practice preferences.

Rodby (11), on the pro side of this debate, presented an argument for unrestricting the use of group II GBCM in patients with CKD stages 4–5, supported by accumulating evidence for absence of NSF in the >3000 patients exposed to GBCM reported in recent papers. He made reference to the aforementioned recent stratified analysis by CKD stage at the request of the National Kidney Foundation in the United States (6). He cautioned against using more than the standard dose, a case in point made in a recently reported patient with CKD stage 3a who developed NSF after 185 days postexposure to 1.5 times the standard dose of the group II GBCM gadoterate (12). This was a major risk factor with group I GBCM and should be avoided with all GBCM. Important notes are made about the sole GBCM in group III being insufficiently studied in patients with CKD, and that direct GBCM nephrotoxicity is not a concern with standard intravenous dosing.

As the debate starts to move beyond the safety of low risk for NSF in group II GBCM in those with CKD stages 4–5, lingering concerns include the potential increase in patients developing NSF as the use of group II GBCM become more unrestricted (13) and the recently reported deposition of gadolinium in the brain, although to a lesser degree with group II GBCM in all patients (14). Other points worth mentioning are not initiating hemodialysis in patients with CKD stages 4–5 for the sole purpose of GBCM removal and, in contrast to patients with ESKD who are anuric, the risk of contrast‐induced nephropathy with iodinated radiocontrast agents is germane to the discussion when assessing risk-benefit ratio in CKD stages 4–5, with the balance tipping in favor of using group II GBCM when needed. In this regard, it remains important to discuss with the radiologist all possible imaging options, including noncontrast magnetic resonance imaging, so as to limit the exposure to GBCM to that which is absolutely needed. This is especially true given that repeat administrations within a short period, or lifetime cumulative exposure, remain of concern.

In summary, the use of group II or low‐risk GBCM will be expected to increase in the coming years in patients with CKD stages 4–5, allowing for better diagnostic information to be obtained, when necessary, in these patients. Although the preponderance of data from recent cohort studies support this approach, as with any matter still under debate, it is important to remain vigilant as clinicians, maintaining strict adherence to the set boundaries for safe use and promptly reporting any adverse events.

Disclosures

The author has nothing to disclose.

Funding

None.

Acknowledgments

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or Kidney360. Responsibility for the information and views expressed herein lies entirely with the author(s).

Author Contribution

A. Abu-Alfa wrote the original draft and reviewed and edited the manuscript.

Footnotes

  • See related debates, “Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: PRO,” and “Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON,” on pages 10–12 and 13–15, respectively.

  • Received October 7, 2020.
  • Accepted October 26, 2020.
  • Copyright © 2021 by the American Society of Nephrology

References

  1. 1.↵
    American College of Radiology Committee on Drugs and Contrast Media: Nephrogenic systemic fibrosis (NSF). In: ACR Manual on Contrast Media, Reston, VA, American College of Radiology, 2020, pp 83–91. Available at: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed October 4, 2020
  2. 2.↵
    1. Abu-Alfa AK
    : Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis 18: 188–198, 2011 https://doi.org/10.1053/j.ackd.2011.03.001
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kanal E,
    2. Patton TJ,
    3. Krefting I,
    4. Wang C
    : Nephrogenic systemic fibrosis risk assessment and skin biopsy quantification in patients with renal disease following gadobenate contrast administration. AJNR Am J Neuroradiol 41: 393–399, 2020 https://doi.org/10.3174/ajnr.A6448
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. McWilliams RG,
    2. Frabizzio JV,
    3. De Backer AI,
    4. Grinberg A,
    5. Maes BD,
    6. Zobel BB,
    7. Gottschalk A
    : Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: The NSsaFe study. J Magn Reson Imaging 51: 607–614, 2020 https://doi.org/10.1002/jmri.26851
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Woolen SA,
    2. Shankar PR,
    3. Gagnier JJ,
    4. MacEachern MP,
    5. Singer L,
    6. Davenport MS
    : Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium‐based contrast agent: A systematic review and meta‐analysis. JAMA Intern Med 180: 223–230, 2020 https://doi.org/10.1001/jamainternmed.2019.5284
    OpenUrl
  6. 6.↵
    1. Shankar PR,
    2. Davenport MS
    : Risk of nephrogenic systemic fibrosis in stage 4 and 5 chronic kidney disease following group II gadolinium‐based contrast agent administration: Subanalysis by chronic kidney disease stage. Radiology 297: 447–448, 2020
    OpenUrl
  7. 7.↵
    1. Abu-Alfa AK
    : Use of gadolinium-based contrast agents in kidney disease patients: Time for change. Am J Kidney Dis 76: 436–439, 2020 https://doi.org/10.1053/j.ajkd.2020.03.011
    OpenUrl
  8. 8.↵
    1. Pun PH,
    2. Crowley S
    : Group II GBCM can be used safely for imaging in stage 4/5 CKD patients: CON [published online ahead of print December 3, 2020]. Kidney360 2: 13–15, 2021 https://doi.org/10.34067/KID.0005572020
  9. 9.↵
    1. Lunyera J,
    2. Mohottige D,
    3. Alexopoulos A-S,
    4. Campbell H,
    5. Cameron CB,
    6. Sagalla N,
    7. Amrhein TJ,
    8. Crowley MJ,
    9. Dietch JR,
    10. Gordon AM,
    11. Kosinski AS,
    12. Cantrell S,
    13. Williams JW Jr.,
    14. Gierisch JM,
    15. Ear B,
    16. Goldstein KM
    : Risk for nephrogenic systemic fibrosis after exposure to newer gadolinium agents: A systematic review. Ann Intern Med 173: 110–119, 2020 https://doi.org/10.7326/M20-0299
    OpenUrl
  10. 10.↵
    1. Girardi M,
    2. Kay J,
    3. Elston DM,
    4. Leboit PE,
    5. Abu-Alfa A,
    6. Cowper SE
    : Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. J Am Acad Dermatol 65: 1095–1106.e7, 2011 https://doi.org/10.1016/j.jaad.2010.08.041
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Rodby R
    : Group II GBCM can be used safely for imaging in stage 4/5 CKD patients: PRO [published online ahead of print December 3, 2020]. Kidney360 2: 10–12, 2021 https://doi.org/10.34067/KID.0005792020
  12. 12.↵
    1. Lim YJ,
    2. Bang J,
    3. Ko Y,
    4. Seo HM,
    5. Jung WY,
    6. Yi JH,
    7. Han SW,
    8. Yu MY
    : Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report. J Korean Med Sci 35: e293, 2020
    OpenUrl
  13. 13.↵
    1. Rudnick MR,
    2. Wahba IM,
    3. Leonberg‐Yoo AK,
    4. Miskulin D,
    5. Litt HI
    : Risks and options with gadolinium‐based contrast agents in patients with CKD: A review [published online ahead of print August 27, 2020]. Am J Kidney Dis
  14. 14.↵
    1. McDonald RJ,
    2. Levine D,
    3. Weinreb J,
    4. Kanal E,
    5. Davenport MS,
    6. Ellis JH,
    7. Jacobs PM,
    8. Lenkinski RE,
    9. Maravilla KR,
    10. Prince MR,
    11. Rowley HA,
    12. Tweedle MF,
    13. Kressel HY
    : Gadolinium retention: A research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology 289: 517–534, 2018 https://doi.org/10.1148/radiol.2018181151
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Kidney360: 2 (1)
Kidney360
Vol. 2, Issue 1
28 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY
Ali K. Abu-Alfa
Kidney360 Jan 2021, 2 (1) 16-19; DOI: 10.34067/KID.0006002020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY
Ali K. Abu-Alfa
Kidney360 Jan 2021, 2 (1) 16-19; DOI: 10.34067/KID.0006002020
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Author Contribution
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Steroids in IgAN
  • PLEX or No PLEX?
Show more Moderator Commentary

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON
  • Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: PRO
  • Google Scholar

Keywords

  • chronic kidney disease
  • Gadolinium
  • magnetic resonance imaging
  • nephrogenic systemic fibrosis

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • Kidney360
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About Kidney360
  • Kidney360 Email Alerts
  • Kidney360 Podcasts
  • Kidney360 RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Disqus Code of Conduct
  • Disqus Information
  • Feedback
  • Follow on Twitter
  • Subscribe to JASN and CJASN

© 2021 American Society of Nephrology

Online ISSN - 2641-7650

Powered by HighWire